Fig. 8

Use of PMVs@PLGA complexes as vectors for therapeutic roles in the MIRI process (1). A Schematic diagram to validate the efficacy of PMVs@PLGA complexes as vectors for the treatment of MIRI. B Images of echocardiograms after treatment of MIRI with PMVs@PLGA complexes carrying the inhibitor of miR-155-5p (antagomir). C Quantitative analysis of echocardiographic findings and detection of biomarkers of myocardial injury. D Images of TTC staining of myocardial tissue and quantitative analysis (scale bars indicate 10 mm). ns no significance; *P < 0.05; **P < 0.01; *** P < 0.001; **** P < 0.0001